Business
BELLUS Health to Present at Biotech Showcase(TM) 2018 Conference
BELLUS Health to Present at Biotech Showcase™ 2018 Conference Canada NewsWi...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nBELLUS Health to Present at Biotech Showcase™ 2018 Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, Jan. 4, 2018\n\n\n\nLAVAL, QC, Jan. 4, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) (\"BELLUS Health\" or the \"Company\"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will provide a corporate overview of the Company, including BLU-5937, its lead program for chronic cough, at the upcoming Biotech Showcase™ 2018 Conference on Tuesday, January 9 at 9:30 am PT (12:30 pm ET) in San Francisco, CA, at the Hilton San Francisco Union Square. \n\nThe presentation will be webcast live and will remain available for three months thereafter on the following link: https://event.webcasts.com/starthere.jsp?ei=1176848&tp_key=b56a86dfad. BELLUS Health's presentation will also be available on the Company's website at www.bellushealth.com following the event.\n\nBiotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. \n\nAbout BELLUS Health (www.bellushealth.com)\n\nBELLUS Health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need. Its pipeline of projects includes the Company's lead drug candidate BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937, a selective P2X3 antagonist, has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies. Chronic...